Retinitis Pigmentosa Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments

  • ID: 4451357
  • Report
  • 121 pages
  • P&S Market Research
1 of 3
Retinitis pigmentosa currently exhibits a growing pipeline with 38 drug candidates.

Retinitis Pigmentosa therapeutics pipeline in 2017

Retinitis pigmentosa, also known as retinitis, is a degenerative eye disease that occurs due to the progressive degeneration of the rod photoreceptor cells in the retina of eye. The study analyzed that the retinitis pigmentosa therapeutics pipeline comprises approximately 38 drug candidates in different stages of development.

Insights on pipeline segments:

Orphan drug designations from the regulatory bodies such as Food and Drug Administration (FDA), European Medicines Agency (EMA) and Ministry of Health, Labour and Welfare (MHLW) is a key driver for the development of pipeline drugs, for treating retinitis pigmentosa. Majority of the pipeline drug candidates are being developed using the intravitreal route of administration. HORAMA S.A. is in the process of developing two phase I/II, and one Pre-Clinical therapeutics for the treatment of retinitis pigmentosa.

Maximum drugs being developed as gene therapy

Many companies are increasingly emphasizing on the development of gene therapy candidates, due to their positive clinical results in the treatment of retinitis pigmentosa. Based on molecule type, around 50.0% of the drug candidates in the retinitis pigmentosa pipeline are expected to be developed based on gene therapy.

Technological advancements spurring the growth of the retinitis pigmentosa therapeutics pipeline

Technological advancements are spurring the pipeline growth, for instance, AAV vector manufacturing platform was used in the development of AGTC-501 by the Applied Genetic Technologies Corp for the treatment of retinitis pigmentosa

Some of the key players developing drugs for the treatment of retinitis pigmentosa include jCyte, Inc., Dompe Farmaceutici SpA, ProRetina Therapeutics, S.L., and Recursion Pharmaceuticals Inc.

Retinitis Pigmentosa Therapeutics Pipeline Analysis:
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Retinitis pigmentosa Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

Chapter 5. Retinitis Pigmentosa Therapeutics Pipeline Analysis by Phase (2017)
5.1 Filed: Drug profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase III: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase II: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Phase I: Drug profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Clinical Trials
5.4.4 Clinical Results
5.4.5 Strategic Development
5.4.6 Designation
5.4.7 Grants
5.4.8 Patent
5.4.9 Technology
5.5 Pre-Clinical: Drug profiles
5.5.1 Pre-Clinical Study
5.5.2 Pre-Clinical Results
5.5.3 Strategic Development
5.5.4 Designation
5.5.5 Grants
5.5.6 Patent
5.5.7 Technology
5.6 Discovery: Drug profiles
5.6.1 Strategic Development
5.6.2 Designation
5.6.3 Grants
5.6.4 Patent
5.6.5 Technology
5.7 Unknown: Drug profiles
5.7.1 Pre-Clinical Study
5.7.2 Pre-Clinical Results
5.7.3 Clinical Trials
5.7.4 Clinical Results
5.7.5 Strategic Development
5.7.6 Designation
5.7.7 Grants
5.7.8 Patent
5.7.9 Technology

Chapter 6. Clinical Trials Analysis
6.1 Clinical Trials by Region for Retinitis Pigmentosa Therapeutics Pipeline
6.2 Clinical Trials by Trial Status for Retinitis Pigmentosa Therapeutics Pipeline

Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking for Retinitis Pigmentosa Therapeutics Pipeline
7.2 SWOT Analysis Retinitis Pigmentosa Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

Chapter 8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

Chapter 9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Pipeline Analysis Of Retinitis Pigmentosa Therapeutics, By Company (2017)
Description Of Phase Filed Drug Candidates
Clinical Trials Of Filed Drug Candidates
Description Of Phase III Drug Candidates
Clinical Trials Of Phase III Drug Candidates
Description Of Phase II Drug Candidates
Clinical Trials Of Phase II Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Discovery Drug Candidates
Description Of Unknown Drug Candidates
Companies - at a Glance

List of Figures
Research Methodology
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
Retinitis Pigmentosa Therapeutics Drug Candidates Under Development (2017)
Retinitis Pigmentosa Pipeline Split, By Molecule Type (2017)
Retinitis Pigmentosa Therapeutics Pipeline Split, By Route Of Administration (2017)
Breakdown Of Clinical Trials, By Region
Breakdown Of Clinical Trials, By Trial Status
Key Players Benchmarking
Swot Analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll